Article
Oncology
Iben Lyskjaer, Neesha Kara, Solange De Noon, Christopher Davies, Ana Maia Rocha, Anna-Christina Strobl, Inga Usher, Craig Gerrand, Sandra J. Strauss, Daniel Schrimpf, Andreas von Deimling, Stephan Beck, Adrienne M. Flanagan
Summary: The study aimed to discover and validate methylation-based biomarkers to detect plasma circulating tumor DNA (ctDNA) in osteosarcoma (OS) patients and explore their utility as prognostic markers. The findings showed the potential of mutation-independent methylation-based ctDNA assays for OS and laid the foundation for further multi-institutional collaborative studies on plasma-derived biomarkers in the management of OS.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy S. Kilburn, Sarah Kernaghan, Laura Moretti, Katie Wilkinson, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Jorge S. Reis-Filho, Michael Hubank, Iris Faull, Kimberly C. Banks, Richard B. Lanman, Isaac Garcia-Murillas, Judith M. Bliss, Alistair Ring, Nicholas C. Turner
Summary: Genomic profiling of advanced breast cancer using plasma circulating tumour DNA sequencing revealed diverse subclonal resistance mutations, with distinct mutational processes identified in ER-positive breast cancer. This study highlights the importance of subclonal diversification in pre-treated advanced breast cancer, presenting novel therapeutic opportunities.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Guanhua Zhu, Yu A. Guo, Danliang Ho, Polly Poon, Zhong Wee Poh, Pui Mun Wong, Anna Gan, Mei Mei Chang, Dimitrios Kleftogiannis, Yi Ting Lau, Brenda Tay, Wan Jun Lim, Clarinda Chua, Tira J. Tan, Si-Lin Koo, Dawn Q. Chong, Yoon Sim Yap, Iain Tan, Sarah Ng, Anders J. Skanderup
Summary: Profiling of ctDNA using local tissue-specific cfDNA degradation patterns accurately estimates ctDNA burden, while predictive power of 6 specific regulatory regions is strong. A quantitative model and compact targeted sequencing enable low-cost tracking of ctDNA dynamics and disease progression across colorectal and breast cancer patients.
NATURE COMMUNICATIONS
(2021)
Review
Biotechnology & Applied Microbiology
Payar Radfar, Hamidreza Aboulkheyr Es, Rob Salomon, Arutha Kulasinghe, Naveen Ramalingam, Ehsan Sarafraz-Yazdi, Jean Paul Thiery, Majid Ebrahimi Warkiani
Summary: Multimodal analysis of circulating tumor cells (CTCs) has the potential to provide significant insights for cancer research, aiding in understanding tumor development and metastasis mechanisms. Investigating CTCs and CTC clusters through single-cell analysis can provide crucial information for cancer treatment and management.
TRENDS IN BIOTECHNOLOGY
(2022)
Editorial Material
Medicine, General & Internal
Mary E. Norton
Summary: The 2022 Lasker-DeBakey Clinical Medical Research Award is awarded to Yuk Ming Dennis Lo for his discovery of fetal DNA in the maternal circulation, which has revolutionized prenatal screening.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Jouni Kujala, Jaana M. Hartikainen, Maria Tengstrom, Reijo Sironen, Paivi Auvinen, Veli-Matti Kosma, Arto Mannermaa
Summary: The study evaluated the concordance between cfDNA and tumor DNA genetic profiles, showing that liquid biopsy can reflect the heterogeneity and clonal evolution of BC, potentially identifying driver variants and therapeutic targets that may be missed in tumor DNA sequencing. Liquid biopsy may aid in the early detection of metastatic BC and support clinical decision-making, despite observed discordance between the two sources of DNA.
Article
Cell & Tissue Engineering
K. M. Tsoi, N. Gokgoz, P. Darville-O'Quinn, P. Prochazka, A. Malekoltojari, A. M. Griffin, P. C. Ferguson, J. S. Wunder, I. L. Andrulis
Summary: This study investigated the prognostic significance of cfDNA and ctDNA in bone and soft-tissue sarcomas, demonstrating their potential as biomarkers despite the lack of recurrent genomic alterations. Patients with lower cfDNA levels showed improved disease-free survival rates. Digital droplet PCR was able to detect tumor-specific alterations in the circulation of sarcoma patients.
BONE & JOINT RESEARCH
(2021)
Article
Hematology
Chong Wei, Wei Wang, Yan Zhang, Danqing Zhao, Wei Zhang, Daobin Zhou
Summary: In this study, the utility of circulating tumor DNA (ctDNA) in peripheral T-cell lymphomas (PTCLs) was evaluated. Plasma cell-free DNA (cfDNA) was obtained and mutational profiling was conducted in 47 patients with newly diagnosed PTCLs. The results showed that ctDNA had high sensitivity and specificity for detecting mutations confirmed by tumor biopsy. Furthermore, ctDNA concentration and number of mutations were strongly correlated with tumor burden indicators and could predict patient outcomes. Longitudinal analysis of ctDNA also showed agreement with radiographic response. Overall, this study suggests that ctDNA may be a promising tool for mutational profiling, tumor burden assessment, outcome prediction, and disease monitoring in PTCLs.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Zeynep B. Zengin, Caroline Weipert, Nicholas J. Salgia, Nazli Dizman, Joann Hsu, Luis Meza, Alexander Chehrazi-Raffle, Ramya Muddasani, Sabrina Salgia, Jasnoor Malhotra, Neal Chawla, Errol J. Philip, Lesli Kiedrowski, Benjamin L. Maughan, Nityam Rathi, Divyam Goel, Toni K. Choueiri, Neeraj Agarwal, Sumanta K. Pal
Summary: This study explores the role of circulating cell-free tumor DNA as an adjunct to tissue genomic profiling in metastic renal cell carcinoma (mRCC), confirming the feasibility and potential of using ctDNA to identify actionable alterations. The study also reveals that ctDNA and tissue-based genomic profiling are complementary, with unique alterations identified by both platforms, and the frequency of unique alterations increases with greater temporal separation between tests.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Cloud P. Paweletz, Grace A. Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C. Chao, Alexander I. Spira, Konstantinos Leventakos, Melissa L. Johnson, Sai-Hong Ignatius Ou, Gregory J. Riely, Kenna Anderes, Wenjing Yang, James G. Christensen, Pasi A. Janne
Summary: This study reports on early ctDNA changes of KRAS G12C in lung cancer patients and suggests that ctDNA changes can be used as a potential measure for early prediction of clinical response.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Sheehyun Kim, Yoojoo Lim, Jun-Kyu Kang, Hwang-Phill Kim, Hanseong Roh, Su Yeon Kim, Dongin Lee, Duhee Bang, Seung-Yong Jeong, Kyu Joo Park, Sae-Won Han, Tae-You Kim
Summary: This study analyzed serial blood samples from metastatic colorectal cancer patients and sequenced ctDNA to evaluate its clinical utility. The results showed that ctDNA clearance after chemotherapy was associated with longer progression-free survival, independent of radiological response. Longitudinal ctDNA monitoring detected ctDNA progression earlier than radiological progressive disease in a significant percentage of patients.
BRITISH JOURNAL OF CANCER
(2022)
Review
Pharmacology & Pharmacy
Liu-Fang Ye, Zi-Yao Huang, Xiao-Xi Chen, Zhi-Gang Chen, Si-Xian Wu, Chao Ren, Ming-Tao Hu, Hua Bao, Ying Jin, Feng Wang, Feng-Hua Wang, Zi-Ming Du, Xue Wu, Huai-Qiang Ju, Yang Shao, Yu-Hong Li, Rui-Hua Xu, De-Shen Wang
Summary: This study aimed to identify mechanisms of drug resistance to the combination of vemurafenib, irinotecan, and cetuximab (VIC) in BRAFV600E metastatic colorectal cancer (mCRC). The results showed that BRAF mutant in baseline plasma and its dynamics are significantly associated with VIC-related response, and concurrent RNF43 mutation significantly sensitises tumour to VIC treatment. VIC resistance frequently involves genes in PI3K, MAPK pathway, and several novel resistance mechanisms such as TGFBR2 and SMAD4 mutations. Additionally, acquired altered genes in DNA damaging repair pathway were identified in 33% of patients after VIC treatment, and these patients with pre-treatment resistance subclones developed inferior responses, along with higher tumour mutation burden both at baseline and progression plasma.
DRUG RESISTANCE UPDATES
(2022)
Review
Oncology
Maria Gabriela O. Fernandes, Natalia Cruz-Martins, Jose Carlos Machado, Jose Luis Costa, Venceslau Hespanhol
Summary: Liquid biopsy, specifically plasma ctDNA analysis, has revolutionized cancer patient management by detecting genomic alterations and resistance mechanisms, particularly in lung cancer patients. While offering a comprehensive view of tumor diversity, its non-invasive nature overcomes the challenges of obtaining tissue samples. Further clarification is needed regarding the use of LB in supporting diagnostic and therapeutic decisions.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Lea Jessica Albrecht, Anna Hoewner, Klaus Griewank, Smiths S. Lueong, Nils von Neuhoff, Peter A. Horn, Antje Sucker, Annette Paschen, Elisabeth Livingstone, Selma Ugurel, Lisa Zimmer, Susanne Horn, Jens T. Siveke, Dirk Schadendorf, Renata Varaljai, Alexander Roesch
Summary: This study identified a new liquid biopsy approach for melanoma diagnosis using circulating cell-free RNA (cfRNA). The cfRNA panel showed high diagnostic accuracy in distinguishing melanoma patients from healthy individuals. Additionally, cfRNA levels could predict patients' survival and therapeutic response.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Yasutoshi Fujii, Atsushi Ono, C. Nelson Hayes, Hiroshi Aikata, Masami Yamauchi, Shinsuke Uchikawa, Kenichiro Kodama, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Wataru Okamoto, Tomokazu Kawaoka, Masataka Tsuge, Michio Imamura, Kazuaki Chayama
Summary: This study showed that ctDNA profiling can detect somatic alterations in most advanced HCC patients, and monitoring ctDNA kinetics during LEN treatment can serve as a useful marker for disease progression. These findings indicate that ctDNA profiling holds promise for providing valuable information in clinical practice.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, Elena Provenzano, Helen A. Bardwell, Wenxin Ma, Wei Cope, Ali Dariush, Sarah-Jane Dawson, Jean E. Abraham, Janet Dunn, Louise Hiller, Jeremy Thomas, David A. Cameron, John M. S. Bartlett, Larry Hayward, Paul D. Pharoah, Florian Markowetz, Oscar M. Rueda, Helena M. Earl, Carlos Caldas
Summary: This study demonstrates that the response to breast cancer treatment is influenced by the pre-treatment tumour ecosystem, and a machine learning model incorporating multi-omic features can predict pathological complete response.
Article
Biochemistry & Molecular Biology
Hendrik J. Kuiken, Sabin Dhakal, Laura M. Selfors, Chandler M. Friend, Tian Zhang, Maurizio Callari, Ron C. J. Schackmann, G. Kenneth Gray, Jett Crowdis, Hyo-Eun C. Bhang, Timour Baslan, Frank Stegmeier, Steven P. Gygi, Carlos Caldas, Joan S. Brugge
Summary: Intratumoral heterogeneity exists in different tumor types and models, affecting tumor progression and drug resistance. In this study, subclonal populations derived from a triple-negative breast cancer cell line showed unique genetic alterations and varied in growth and tumor forming ability. Clonal dynamics analysis revealed selection for distinct populations in different environments, with one subclone showing selective advantage and decreased sensitivity to interferon signaling in xenograft tumors, suggesting potential implications for cancer and xenograft models.
Editorial Material
Oncology
Carlos Caldas, Maria Rescigno, Samra Turajlic, Anant Madabhushi, Zemin Zhang, Piro Lito, Christine E. Brown, Klaus Pantel, John Haanen, Narjust Duma
Summary: In the past 20 years, cancer research has entered a new era, shifting its focus from cancer cells themselves to the complex interactions within the tumor and with the host, which ultimately determine the evolution and progression of the disease. The development of immunotherapies and new diagnostic strategies has changed the fate of many patients and has the potential to revolutionize clinical practice.
Meeting Abstract
Oncology
Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Karen Van Baelen, Maxim De Schepper, Sophia Leduc, Edoardo Isnaldi, Sam Aparicio, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Andrew Green, Hazem Khout, Eyfjoro Jorunn, Stian Knappskog, Savitri Krishnamurthy, Sunil Lakhani, Anita Langerod, John W. M. Martens, Leigh Murphy, Serena Nik-Zainal, Colin Purdie, Emad Rakha, Andrea Richardson, Anne Salomon, Peter Simpson, Christos Sotiriou, Paul Span, Benita Kiat-Tee Tan, Alastair Thompson, Stefania Tommasi, Marc Van De Vijver, Steven Van Laere, Alain Viari, Giuseppe Floris, Elia Biganzoli, Francois Richard, Christine Desmedt
Article
Oncology
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, Flaminia Pedretti, Alejandro Moles-Fernandez, Cristina Viaplana, Guillermo Villacampa, Marta Guzman, Olga Rodriguez, Judit Grueso, Jose Jimenez, Enrique J. Arenas, Andrea Degasperi, Joao M. L. Dias, Josep Forment, Mark J. O'Connor, Olivier Deas, Stefano Cairo, Yinghui Zhou, Antonino Musolino, Carlos Caldas, Serena Nik-Zainal, Robert B. Clarke, Paolo Nuciforo, Orland Diez, Xavier Serres-Creixams, Vicente Peg, Martin Espinosa-Bravo, Teresa Macarulla, Ana Oaknin, Joaquin Mateo, Joaquin Arribas, Rodrigo Dienstmann, Meritxell Bellet, Mafalda Oliveira, Cristina Saura, Sara Gutierrez-Enriquez, Judith Balmana, Violeta Serra
Summary: PARP inhibitors are approved drugs for certain cancers such as ovarian, breast, prostate, and pancreatic cancers. This study validated a new test method for predicting patient response to PARPi and platinum-based therapies, showing higher accuracy compared to other detection methods. The results support further clinical assessment of this test in patient samples.
Article
Genetics & Heredity
Esther Danenberg, Helen Bardwell, Vito R. T. Zanotelli, Elena Provenzano, Suet-Feung Chin, Oscar M. Rueda, Andrew Green, Emad Rakha, Samuel Aparicio, Ian O. Ellis, Bernd Bodenmiller, Carlos Caldas, H. Raza Ali
Summary: Imaging mass cytometry profiling of 693 breast tumors revealed 10 recurrent tumor microenvironment spatial structures, associated with genomic profiles and outcomes. These multicellular structures within the TME, varying in vascular content, stromal activation, and leukocyte composition, could improve patient stratification and link spatial organization to local TME function.
Article
Oncology
Lorenzo Gerratana, Jean-Yves Pierga, James M. Reuben, Andrew A. Davis, Firas H. Wehbe, Luc Dirix, Tanja Fehm, Franco Nole, Rafael Gisbert-Criado, Dimitrios Mavroudis, Salvatore Grisanti, Jose A. Garcia-Saenz, Justin Stebbing, Carlos Caldas, Paola Gazzaniga, Luis Manso, Rita Zamarchi, Marta Bonotto, Angela Fernandez de Lascoiti, Leticia De Mattos-Arruda, Michail Ignatiadis, Maria-Teresa Sandri, Daniele Generali, Carmine De Angelis, Sarah-Jane Dawson, Wolfgang Janni, Vicente Caranana, Sabine Riethdorf, Erich-Franz Solomayer, Fabio Puglisi, Mario Giuliano, Klaus Pantel, Francois-Clement Bidard, Massimo Cristofanilli
Summary: This study developed a classifier for prognostic simulation of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) patients. The classifier accurately predicted patients' prognosis and stratified them into different clinical subgroups. It also revealed differential prognostic impact of endocrine therapy (ET) and chemotherapy (CT) in different subgroups.
Article
Cell Biology
Nishanth Belugali Nataraj, Ashish Noronha, Joo Sang Lee, Soma Ghosh, Harsha Raj Mohan Raju, Arunachalam Sekar, Binyamin Zuckerman, Moshit Lindzen, Emilio Tarcitano, Swati Srivastava, Michael Selitrennik, Ido Livneh, Diana Drago-Garcia, Oscar Rueda, Carlos Caldas, Sima Lev, Tamar Geiger, Aaron Ciechanover, Igor Ulitsky, Rony Seger, Eytan Ruppin, Yosef Yarden
Summary: By establishing multi-omics pipelines, we discovered that overexpression of NUP93 is associated with aggressive human mammary tumors, enhancing their migration and invasion capabilities. NUP93 is involved in nuclear transport, activating various signaling pathways and ultimately contributing to tumor growth and metastasis. Targeting this nuclear transport process with myristoylated peptides can inhibit tumor growth and metastasis.
Article
Oncology
Tom van den Bosch, Oscar M. Rueda, Carlos Caldas, Louis Vermeulen, Daniel M. Miedema
Summary: This study found that low-risk breast cancer patients identified using chromosomal copy-number ITH do not benefit from adjuvant endocrine therapy.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Xiaoyu Wang, Puya Gharahkhani, David M. Levine, Rebecca C. Fitzgerald, Ines Gockel, Douglas A. Corley, Harvey A. Risch, Leslie Bernstein, Wong-Ho Chow, Lynn Onstad, Nicholas J. Shaheen, Jesper Lagergren, Laura J. Hardie, Anna H. Wu, Paul D. P. Pharoah, Geoffrey Liu, Lesley A. Anderson, Prasad G. Iyer, Marilie D. Gammon, Carlos Caldas, Weimin Ye, Hugh Barr, Paul Moayyedi, Rebecca Harrison, R. G. Peter Watson, Stephen Attwood, Laura Chegwidden, Sharon B. Love, David MacDonald, John DeCaestecker, Hans Prenen, Katja Ott, Susanne Moebus, Marino Venerito, Hauke Lang, Rupert Mayershofer, Michael Knapp, Lothar Veits, Christian Gerges, Josef Weismueller, Matthias Reeh, Markus M. Noethen, Jakob R. Izbicki, Hendrik Manner, Horst Neuhaus, Thomas Roesch, Anne C. Boehmer, Arnulf H. Hoelscher, Mario Anders, Oliver Pech, Brigitte Schumacher, Claudia Schmidt, Thomas Schmidt, Tania Noder, Dietmar Lorenz, Michael Vieth, Andrea May, Timo Hess, Nicole Kreuser, Jessica Becker, Christian Ell, Ian Tomlinson, Claire Palles, Janusz A. Jankowski, David C. Whiteman, Stuart MacGregor, Johannes Schumacher, Thomas L. Vaughan, Matthew F. Buas, James Y. Dai
Summary: This study identified novel genetic susceptibility loci for esophageal adenocarcinoma and Barrett esophagus using an eQTL set-based genetic association approach, expanding the pool of genetic susceptibility loci.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Biology
Sophia A. Wild, Ian G. Cannell, Ashley Nicholls, Katarzyna Kania, Dario Bressan, Gregory J. Hannon, Kirsty Sawicka
Summary: This study utilizes clonal transcriptomics with WILD-seq to analyze mouse models of TNBC and identifies NRF2 as a major mechanism of taxane resistance. It also discovers the collateral sensitivity of tumor models to asparagine deprivation therapy using L-asparaginase after docetaxel treatment.
Article
Multidisciplinary Sciences
Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, Maxim De Schepper, Mauro Delorenzi, Caroline A. Drukker, Annuska M. Glas, Andrew R. Green, Edoardo Isnaldi, Jorunn Eyfjoro, Hazem Khout, Stian Knappskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart Reed, Leigh Murphy, Stefan Naulaerts, Serena Nik-Zainal, Ines Nevelsteen, Patrick Neven, Martine Piccart, Coralie Poncet, Kevin Punie, Colin Purdie, Emad A. Rakha, Andrea Richardson, Emiel Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Span, Kiat Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen Van Baelen, Marc Van de Vijver, Steven Van Laere, Laura van't Veer, Giuseppe Viale, Alain Viari, Hanne Vos, Anke T. Witteveen, Hans Wildiers, Giuseppe Floris, Abhishek D. Garg, Ann Smeets, Diether Lambrechts, Elia Biganzoli, Francois Richard, Christine Desmedt
Summary: Obesity is associated with an increased risk of developing breast cancer and worse prognosis in breast cancer patients. This study investigates the biological differences in untreated primary breast cancer according to patients' body mass index (BMI). The study finds several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. It also reveals an elevated and unresolved inflammation of the breast cancer tumor microenvironment associated with obesity. The findings suggest that patient adiposity may play a significant role in the heterogeneity of breast cancer and should be considered for tailored treatment.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Edwin Cuppen, Olivier Elemento, Richard Rosenquist, Svetlana Nikic, Maarten IJzerman, Isabelle Durand Zaleski, Geert Frederix, Lars-Ake Levin, Charles G. Mullighan, Reinhard Buettner, Trevor J. Pugh, Sean Grimmond, Carlos Caldas, Fabrice Andre, Ilse Custers, Elias Campo, Hans van Snellenberg, Anna Schuh, Hidewaki Nakagawa, Christof von Kalle, Torsten Haferlach, Stefan Froehling, Vaidehi Jobanputra
Summary: The combination of whole-genome and transcriptome sequencing (WGTS) is a comprehensive precision diagnostic test that is expected to transform diagnosis and treatment for cancer patients. However, there are barriers to the implementation and widespread adoption of this test, including considerations of utility in different cancer types, cost-effectiveness and affordability.
JCO PRECISION ONCOLOGY
(2022)
Review
Oncology
Emily A. Kolyvas, Carlos Caldas, Kathleen Kelly, Saif S. Ahmad
Summary: Breast cancer is a common and deadly cancer, and the role of AR in this type of cancer is still not fully understood. However, targeting AR in breast cancer may have therapeutic potential and further research is needed for effective treatment.
BREAST CANCER RESEARCH
(2022)
Correction
Oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Brana, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Judith Balmana, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Frohling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtio
Article
Oncology
Andra S. Martinikova, Miroslav Stoyanov, Anna Oravetzova, Yannick P. Kok, Shibo Yu, Jana Dobrovolna, Pavel Janscak, Marcel van Vugt, Libor Macurek
Summary: Oncogene-induced replication stress is a major cause of genome instability in cancer cells. This study reveals that increased activity of PPM1D exacerbates replication stress caused by cyclin E1 overexpression, leading to abnormal cell cycle progression and accumulation of DNA copy number alterations. Pharmacological inhibition of PPM1D can alleviate replication stress-induced genome instability.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Alamelu G. Bharadwaj, Meghan E. McLean, Margaret L. Dahn, Hannah F. Cahill, Marie-Claire D. Wasson, Raj Pranap Arun, Olivia L. Walker, Brianne M. Cruickshank, Wasundara Fernando, Jaganathan Venkatesh, Penelope J. Barnes, Gillian Bethune, Gregory Knapp, Lucy K. Helyer, Carman A. Giacomantonio, David M. Waisman, Paola Marcato
Summary: ALDH1A3 regulates the plasminogen activation pathway to promote breast cancer metastasis. Co-expression of ALDH1A3 and tPA is associated with TNBC subtype, high tumor grade, and recurrent metastatic disease.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nuria Gendrau-Sanclemente, Agnes Figueras, Kristina Gracova, Alvaro Lahiguera, Elisenda Alsina-Sanchis, Juan A. Marin-Jimenez, August Vidal, Xavier Matias-Guiu, Sergi Fernandez-Gonzalez, Marc Barahona, Lola Marti, Jordi Ponce, Francesc Vinals
Summary: High-grade serous ovarian cancer (HGSOC), the deadliest gynecological malignancy, spreads through transcoelomic dissemination. This study reveals that platelet-derived growth factor receptor beta (PDGFRβ) is essential for the formation of tumorspheres in HGSOC. Inhibition of PDGFRβ blocks the clustering of ovarian cancer cells and prevents peritoneal dissemination.
MOLECULAR ONCOLOGY
(2024)
